Herbicide-resistant Grain Sorghum

A fluazifop-resistant sorghum cultivar designated ‘21534_ACCase-R’ and plants comprising a polynucleotide encoding the polypeptide of SEQ ID NO: 39 are disclosed herein. The present invention provides seeds, plants, and plant parts derived from sorghum cultivar ‘21534_ACCase-R’ and those including SEQ ID NO: 39. Further, it provides methods for producing a sorghum plant by crossing ‘21534_ACCase-R’ with itself or another sorghum variety. The invention also encompasses any sorghum seeds, plants, and plant parts produced by the methods disclosed herein, including those in which additional traits have been transferred into ‘21534_ACCase-R’ through the introduction of a transgene or by breeding ‘21534_ACCase-R’ with another sorghum cultivar

Herbicide-resistant Grain Sorghum

A fluazifop-resistant sorghum cultivar designated ‘21534_ACCase-R’ and plants comprising a polynucleotide encoding the polypeptide of SEQ ID NO: 39 are disclosed herein. The present invention provides seeds, plants, and plant parts derived from sorghum cultivar ‘21534_ACCase-R’ and those including SEQ ID NO: 39. Further, it provides methods for producing a sorghum plant by crossing ‘21534_ACCase-R’ with itself or another sorghum variety. The invention also encompasses any sorghum seeds, plants, and plant parts produced by the methods disclosed herein, including those in which additional traits have been transferred into ‘21534_ACCase-R’ through the introduction of a transgene or by breeding ‘21534_ACCase-R’ with another sorghum cultivar

Genome evolution in the genus Sorghum (Poaceae)

BACKGROUND AND AIMS: The roles of variation in DNA content in plant evolution and adaptation remain a major biological enigma. Chromosome number and 2C DNA content were determined for 21 of the 25 species of the genus Sorghum and analysed from a phylogenetic perspective. METHODS: DNA content was determined by flow cytometry. A Sorghum phylogeny was constructed based on combined nuclear ITS and chloroplast ndhF DNA sequences. KEY RESULTS: Chromosome counts (2n = 10, 20, 30, 40) were, with few exceptions, concordant with published numbers. New chromosome numbers were obtained for S. amplum (2n = 30) and S. leiocladum (2n = 10). 2C DNA content varies 8.1-fold (1.27-10.30 pg) among the 21 Sorghum species. 2C DNA content varies 3.6-fold from 1.27 pg to 4.60 pg among the 2n = 10 species and 5.8-fold (1.52-8.79 pg) among the 2n = 20 species. The x = 5 genome size varies over an 8.8-fold range from 0.26 pg to 2.30 pg. The mean 2C DNA content of perennial species (6.20 pg) is significantly greater than the mean (2.92 pg) of the annuals. Among the 21 species studied, the mean x = 5 genome size of annuals (1.15 pg) and of perennials (1.29 pg) is not significantly different. Statistical analysis of Australian species showed: (a) mean 2C DNA content of annual (2.89 pg) and perennial (7.73 pg) species is significantly different; (b) mean x = 5 genome size of perennials (1.66 pg) is significantly greater than that of the annuals (1.09 pg); (c) the mean maximum latitude at which perennial species grow (-25.4 degrees) is significantly greater than the mean maximum latitude (-17.6) at which annual species grow. CONCLUSIONS: The DNA sequence phylogeny splits Sorghum into two lineages, one comprising the 2n = 10 species with large genomes and their polyploid relatives, and the other with the 2n = 20, 40 species with relatively small genomes. An apparent phylogenetic reduction in genome size has occurred in the 2n = 10 lineage. Genome size evolution in the genus Sorghum apparently did not involve a 'one way ticket to genomic obesity' as has been proposed for the grasses

Measuring the quality and quantity of professional intrapartum support: Testing a computerised systematic observation tool in the clinical setting

Background: Continuous support in labour has a significant impact on a range of clinical outcomes, though whether the quality and quantity of support behaviours affects the strength of this impact has not yet been established. To identify the quality and quantity of support, a reliable means of measurement is needed. To this end, a new computerised systematic observation tool, the ‘SMILI' (Supportive Midwifery in Labour Instrument) was developed. The aim of the study was to test the validity and usability of the ‘Supportive Midwifery in Labour Instrument' (SMILI) and to test the feasibility and acceptability of the systematic observation approach in the clinical intrapartum setting. Methods: Systematic observation was combined with a postnatal questionnaire and the collection of data about clinical processes and outcomes for each observed labour. The setting for the study was four National Health Service maternity units in Scotland, UK. Participants in this study were forty five midwives and forty four women. The SMILI was used by trained midwife observers to record labour care provided by midwives. Observations were undertaken for an average of two hours and seventeen minutes during the active first stage of labour and, in 18 cases, the observation included the second stage of labour. Content validity of the instrument was tested by the observers, noting the extent to which the SMILI facilitated the recording of all key aspects of labour care and interactions. Construct validity was tested through exploration of correlations between the data recorded and women's feelings about the support they received. Feasibility and usability data were recorded following each observation by the observer. Internal reliability and construct validity were tested through statistical analysis of the data. Results: One hundred and four hours of labour care were observed and recorded using the SMILI during forty nine labour episodes. Conclusion: The SMILI was found to be a valid and reliable instrument in the intrapartum setting in which it was tested. The study identified that the SMILI could be used to test correlations between the quantity and quality of support and outcomes. The systematic observational approach was found to be an acceptable and feasible method of enquiry

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Sorghum bicolor x S. halepense interspecific hybridization is influenced by the frequency of 2n gametes in S. bicolor

Tetraploid johnsongrass [Sorghum halepense (L.) Pers.] is a sexually-compatible weedy relative of diploid sorghum [Sorghum bicolor (L.) Moench]. To determine the extent of interspecific hybridization between male sterile grain sorghum and johnsongrass and the ploidy of their progeny, cytoplasmic (CMS), genetic (GMS) and chemically induced male sterile lines of Tx623 and Tx631 were pollinated with johnsongrass pollen. At maturity 1% and 0.07% of the developing seeds of Tx623 and Tx631 respectively were recovered. Ninety-one percent of recovered hybrids were tetraploid and two percent were triploid, the tetraploids resulting from 2n gametes present in the sorghum female parent. Their formation appears to be genotype dependent as more tetraploids were recovered from Tx623 than Tx631. Because a tetraploid sorghum x johnsongrass hybrid has a balanced genome, they are male and female fertile providing opportunities for gene flow between the two species. Given the differences in 2n gamete formation among Tx623 and Tx631, seed parent selection may be one way of reducing the likelihood of gene flow. These studies were conducted in controlled and optimum conditions; the actual outcrossing rate in natural conditions is expected to be much lower. More studies are needed to assess the rates of hybridization, fitness, and fertility of the progeny under field conditions.USDA-NIFA Biotechnology Risk Assessment Grant [2017-33522-27030]; USDA-ARSUnited States Department of Agriculture (USDA) [58-3020-7-028]Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Intergeneric hybrid plants and methods for production thereof

Methods for the production of an intergeneric hybrid plants and plants produced thereby. In certain aspects, intergeneric hybrid plants are produced by crossing a sorghum parent plant comprising a mutant sorghum iap allele with a second moncot plant. Methods for the use of such plants and products obtained therefrom are also provided.U